A Pilot Study of Single-Dose Azithromycin Versus Three-Day Azithromycin or Single-Dose Ceftriaxone for Uncomplicated Acute Otitis Media in Children

Current Therapeutic Research - Clinical and Experimental

Volumn 64, Issue SUPPL. A, 2003, Pages

  Arguedas, Adriano ^a,c   Loaiza, Cecilia ^a   Perez, Alexandra ^a   Gutierrez, Alvaro ^a   Herrera, Marco Luis ^a   Rothermel, Constance D ^b  

^a HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

^b PFIZER INC   (United States)

^c Inst de Atencion Pediat   (Costa Rica)

Author keywords

Acute otitis media; Azithromycin; Ceftriaxone; Haemophilus influenzae; Short course therapy; Streptococcus pneumoniae

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE;

ACUTE DIARRHEA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; EVALUATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROBIOLOGICAL EXAMINATION; MYRINGOTOMY; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SEROUS OTITIS MEDIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VOMITING; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; HAEMOPHILUS INFLUENZAE; INFANT; MORAXELLA CATARRHALIS; OTITIS MEDIA; PILOT STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RASH; STREPTOCOCCUS PNEUMONIAE;

EID: 0344549581     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(03)80014-0     Document Type: Article

References (48)

1. Klein JO. Otitis media. Clin Infect Dis. 1994;19:823-833.
2. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:1-9.
3. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J. 1997;16:680-695.
4. Dowell SF, Marcy SM, Phillips WR, et al. Otitis media - principles of judicious use of antimicrobial agents. Pediatrics. 1998;101:165-171.
5. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279:365-370.
6. Kozyrskyi AL, Hildes-Ripstein GE, Longstaffe SE, et al. Treatment of acute otitis media with a shortened course of antibiotics: A meta-analysis. JAMA. 1998;279: 1736-1742.
7. Paradise JL. Short-course antimicrobial treatment for acute otitis media: Not best for infants and young children. JAMA. 1997;278:1640-1642.
8. Varsano I, Frydman M, Amir J, Alpert G. Single intramuscular dose of ceftriaxone as compared to 7-day amoxicillin therapy for acute otitis media in children. A double-blind clinical trial. Chemotherapy. 1988;34(Suppl 1):39-46.
9. Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for acute otitis media in children. Pediatrics. 1993;91:23-30.
10. Chamberlain JM, Boenning DA, Waisman Y, et al. Single-dose ceftriaxone versus 10 days of cefaclor for otitis media. Clin Pediatr (Phila). 1994;33:642-646.
11. Barnett ED, Teele DW, Klein JO, et al. Comparison of ceftriaxone and trimethoprimsulfamethoxazole for acute otitis media. Greater Boston Otitis Media Study Group. Pediatrics. 1997;99:23-28.
12. Varsano I, Volovitz B, Horev Z, et al. Intramuscular ceftriaxone compared with oral amoxicillin-clavulanate for treatment of acute otitis media in children. Eur J Pediatr. 1997;156:858-863.
13. Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: Clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J. 1999;18:403-409.
14. Rocephin [package insert]. Nutley, New Jersey: Roche Pharmaceuticals; 2000.
15. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73-82.
16. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother. 1993;31(Suppl E):39-50.
17. McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J. 1996;15(Suppl 9):S20-S23.
18. Aronovitz G. A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J. 1996;15(Suppl 9):S15-S19.
19. Khurana CM. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J. 1996;15(Suppl 9):S24-S29.
20. Strache S. Multicenter comparative study of once-daily azithromycin vs. three-times daily cefaclor in the treatment of children with acute otitis media. Presented at the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides (ICMASK), Barcelona, Spain. January 21-23, 1998.
21. Pestalozza G, Cioce C, Facchini M. Azithromycin in upper respiratory tract infections: A clinical trial in children with otitis media. Scand J Infect Dis Suppl. 1992;83:22-25.
22. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother. 1993;31(Suppl E):65-71.
23. Mohs E, Rodriguez-Solares A, Rivas E, el Hoshy Z. A comparative study of azithromycin and amoxicillin in paediatric patients with acute otitis media. J Antimicrob Chemother. 1993;31(Suppl E):73-79.
24. Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. J Antimicrob Chemother. 1993; 31(Suppl E):81-88.
25. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis. 1995;14:669-676.
26. Arguedas A, Loaiza C, Rodriguez F, et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. J Chemother. 1997;9:44-50.
27. Dunne MW, Latiolais T, Lewis B, et al. A randomized, double blind study of three days of azithromycin compared with amoxicillin clavulanate for the treatment of acute otitis media (AOM). Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2001; Chicago, Illinois. Abstract G-1532.
28. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother. 1996;37(Suppl C):53-61.
29. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST surveillance program (1998-2002). Clin Infect Dis. 2003;36:963-970.
30. Hoban DJ, Doern GV, Fluit C, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis. 2001;32: S81-S93.
31. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother. 2000;44:43-50.
32. Amsden GW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother. 2001;47:61-66.
33. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Fourth informational supplement, M7A3. Villanova, Pa: National Committee for Clinical Laboratory Standards, 1994.
34. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial testing: Twelfth informational supplement, M100-S12. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2002.
35. Pichichero ME. Short course antibiotic therapy for respiratory infections: A review of the evidence. Pediatr Infect Dis J. 2000;19:929-937.
36. Block SL, Arrieta A, Seibel M, et al. Single-dose (30 mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate for the treatment of uncomplicated acute otitis media. Curr Ther Res Clin Exp. 2003;64(Suppl A):A30-A42.
37. Dunne MW, Khurana C, Arguedas A, et al. Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. Antimicrob Agents Chemother. 2003;47:2663-2665.
38. Myers R. Preschool education in Latin America. Inter-American Dialogue. November 1995.
39. Arguedas A, Loaiza C, Perez A, et al. Microbiology of acute otitis media in Costa Rican children. Pediatr Infect Dis J. 1998;17:680-689.
40. Arguedas A, Loaiza C, Knudsen KA, et al. Otitis media (OM) in Costa Rican (CR) children. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, 2002. Abstract G-846.
41. Dagan R, McCracken GH. Flaws in design and conduct of clinical trials in acute otitis media. Pediatr Infect Dis J. 2002;21:894-902.
42. Guidance for Industry, Acute Otitis Media - Developing Antimicrobial Drugs for Treatment. 1998. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
43. Paradise JL. A 15-month-old child with recurrent otitis media. JAMA. 2002;288:2589-2598.
44. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin/clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother. In press.
45. Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J. 2001;20:1-5.
46. Treadway G, Pontani D. Paediatric safety of azithromycin: Worldwide experience. J Antimicrob Chemother. 1996;37(Suppl C):143-149.
47. Treadway G, Reisman A. Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. Int J Antimicrob Agents. 2001;18:427-431.
48. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City -turning the tide. N Engl J Med. 1995;333:229-233.